GLP-1 "shots" are injectable receptor agonists used in weight management. This PlexusDx explainer covers how the injection changes appetite, what the trials measured, who should avoid it, and how genes like FTO shape the metabolic terrain underneath any decision.

GLP-1 receptor agonists are widely discussed for weight loss. This guide explains how the pathway works, what the published trial programs show, the FDA labeling context as of April 2026, the limitations and contraindications worth knowing, and the genetic variables that sit upstream of every GLP-1 decision.

"GLP-1 drugs for weight loss" searches want the clinical record. This article covers the weight-relevant mechanism, the trial-reported reduction range, the FDA-approved weight-management products, the class safety limits, and the inherited variables that PlexusDx maps behind each individual person's outcome.

This overview covers the tirzepatide injection in the context of weight management, from its GIP and GLP-1 dual-agonist mechanism to what the SURPASS and SURMOUNT programs report, the contraindications worth knowing, and the genetic variables that sit upstream of any protocol decision.

This page focuses on the injectable side of Wegovy, why the drug is delivered by injection, how the once-weekly format supports its GLP-1 mechanism, what the STEP program reported, and who the injection is not right for, finishing with genetic context.

Tirzepatide is widely searched for weight loss. This explainer covers the dual-agonist mechanism, what the SURPASS and SURMOUNT trial programs reported, the FDA-approved indications and labeling timeline, and the contraindications worth knowing — grounding a common search in mechanism and published evidence rather than hype.

GLP-1 receptor agonists became famous for weight loss, but the effect is downstream biology, not a shortcut. This PlexusDx explainer traces the appetite mechanism, reviews what the weight trials actually measured, notes where results reach their limits, and shows how genes like FTO shape the metabolic terrain first.

Wegovy weight loss is a phrase carrying a lot of expectation. This page grounds it in the receptor-level mechanism, the STEP trial findings reported in the literature, the FDA-approved indication, and the contraindications worth knowing, followed by honest genetic context.

A clinical view of Mounjaro for weight loss as of April 2026: the dual GIP/GLP-1 mechanism, what the SURPASS trials actually reported, the FDA labeling and contraindications that govern its use, and the upstream genetic variables that PlexusDx analyzes first, before any protocol decision.

This overview walks through how semaglutide is weighed clinically for weight loss, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approved indications, contraindications, and the inherited variables that shape any GLP-1 decision. Facts stay tied to published labeling and literature, not guarantees.

Trulicity is a long-acting GLP-1 receptor agonist that many people search in a weight-loss context. This guide walks through its receptor-level mechanism, the AWARD and REWIND trial evidence, its FDA-approved indications, the boxed warning, and the genetic variants that sit upstream of every GLP-1 conversation.

Semaglutide side effects are well documented in the FDA label and trial programs. This page covers the symptoms most people notice first, the serious risks and boxed warning, the red flags that warrant a call, and how genetics adds pathway context to the tolerability picture.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Disclaimer: The products promoted on this page are intended strictly for laboratory and scientific research use only. They are not approved by the FDA for human consumption, diagnosis, or clinical treatment. Portions of this page contain affiliate links, meaning we earn a commission if you make a purchase through our partner links at no extra cost to you.

Searches for Mounjaro and weight loss usually want two things: how the molecule actually works and what the studies found. This page walks through the dual-receptor mechanism, the SURPASS evidence range, FDA labeling context, who should avoid it, and the genetic variables underneath every GLP-1 decision.

Ozempic reaches most people through the weight-loss conversation, though its FDA label is for type 2 diabetes. This page separates mechanism from marketing: how semaglutide acts at the GLP-1 receptor, what the published trials report, and the genetics beneath it all.

Wegovy is semaglutide, a GLP-1 receptor agonist studied for chronic weight management. This page explains the appetite-and-glucose mechanism, what the STEP trial program reported, the FDA label limits, key safety signals, and how your genetic starting point fits the conversation.

Trulicity (dulaglutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

This overview focuses on the injectable form of semaglutide for weight management, from its GLP-1 mechanism and the SUSTAIN, STEP, and PIONEER evidence to approvals, contraindications, and the inherited variants that shape metabolism. Every figure stays anchored to published labeling and literature.

GLP-1 receptor agonists have reshaped the way people talk about weight management. This overview explains the mechanism in plain terms, walks through the major trial programs and their reported effect sizes, traces the approval timeline, flags the key limitations, and shows how inherited traits shape the metabolic picture.

Rybelsus (oral semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Ozempic Vulva explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.

Mounjaro (tirzepatide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Ozempic (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Wegovy (semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Ozempic Face explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.